Andrx Expects “Near Term” FDA Response To Petition Blocking Concerta Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
McNeil’s citizen petition requests FDA apply additional bioequivalence requirements for Concerta ANDAs. With no patent exclusivity remaining on the innovator product, multiple generics could be approved if FDA rejects McNeil’s arguments.
You may also be interested in...
J&J Dismisses Concerta Patent Suit Against Impax
"Odd" case against the first-filer ends, but litigation with Andrx continues.
J&J Dismisses Concerta Patent Suit Against Impax
"Odd" case against the first-filer ends, but litigation with Andrx continues.
Shire Citizen Petition Seeks to Block Adderall XR Generics
The timing of Shire's petition likely was influenced by the forthcoming end of the 30-month stay on Barr's ANDA.